On October 8, 2018 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, reported that its Chief Scientific Officer Christopher G. Twitty, PhD, will give a presentation during the Advances In Immuno-Oncology Congress being held in San Diego, October 11-12 (Press release, OncoSec Medical, OCT 8, 2018, View Source [SID1234529803]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Twitty’s presentation, titled Intratumoral IL-12 in Combination with Pembrolizumab to Treat Metastatic Melanoma in Patients Unlikely to Respond to Anti PD-1 Therapies: Insights Gained from a Biomarker Program, will discuss ongoing research of TAVO (tavokinogene telseplasmid) in combination with KEYTRUDA(pembrolizumab) as a potential treatment for metastatic melanoma.
The Immuno-Oncology USA Congress will feature over 20 presentations from companies at the forefront of immune-oncology, each presenting insights on new technologies, clinical discoveries and future targets in immuno-oncology research, from cancer vaccines to checkpoint inhibitors, alongside in-depth discussion of patient stratification and clinical development.
"Melanoma is but one of the many types of cancers where the largest part of the immune checkpoint market has yet to be unlocked due to poor/failed/no responses to checkpoint monotherapy, the so-called ‘cold tumor’ problem, which is well known to this audience," said Dr. Twitty, Chief Scientific Officer of OncoSec. "We are excited to share our finding with them indicating TAVO’s ability to recruit more tumor infiltrating lymphocytes (TILs) into the tumors, paving the way for checkpoints to be effective in the largest, but still unresponsive, segment of the checkpoint market."
Details of the presentation are as follows:
Session Title: Translational Immuno-Oncology and Clinical Development
Presentation Title: Intratumoral IL-12 in combination with pembrolizumab to treat metastatic melanoma in patients unlikely to respond to anti PD-1 therapies: Insights gained from a biomarker program
Date and Time: Thursday, October 11, 2018 12:00 PM – 12:30 PM PST
Location: The San Diego Convention Center, Conference Room 5